


## Broxaldine

<b>Cat. No.:</b>	HY-B1143		
<b>CAS No.:</b>	3684-46-6		
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>11</sub> Br <sub>2</sub> NO <sub>2</sub>		
<b>Molecular Weight:</b>	421.08		
<b>Target:</b>	Parasite; Fungal; Bacterial		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 8.33 mg/mL (19.78 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.3748 mL	11.8742 mL	23.7485 mL
		5 mM	0.4750 mL	2.3748 mL	4.7497 mL
10 mM		0.2375 mL	1.1874 mL	2.3748 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (1.97 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (1.97 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Broxaldine (Brobenzoxaldine) is an antiprotozoal agent. Broxaldine inhibits <i>Clostridium difficile</i> with a MIC value of 4 μM, and has antifungal effects <sup>[1][2]</sup> .
<b>In Vitro</b>	Broxaldine (Brobenzoxaldine) is an antiprotozoal drug. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Hazra SK, et al. Therapeutic trial of a combination of broxyquinoline and brobenzoxaldine in the treatment of leprosy. Lepr India. 1979 Oct;51(4):505-10.

[2]. AbdelKhalek A, et al. Screening for potent and selective anticlostridial leads among FDA-approved drugs. J Antibiot (Tokyo). 2020 Mar 4.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA